13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001799883
Total reported value
$287.9M
$287.9M
28 檔
88.8%
In Q2 2024, 5AM Venture Management, LLC's U.S. equity holdings reached a combined market value of $287.9M, distributed across 28 disclosed stock positions.
During Q2 2024, 5AM Venture Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SKYE | Skye Bioscience Inc | Stock-Other | 18.24% | +0.68% | — | |
| 2 | TRDA | Entrada Therapeutics Inc | Stock-Other | 14.05% | -3.84% | — | |
| 3 | ELVN | Enliven Therapeutics Inc | Stock-Other | 13.65% | — | -31.94% | |
| 4 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 7.14% | — | -0.73% | |
| 5 | CLDX | Celldex Therapeutics Inc | Stock-Other | 4.12% | +2.05% | — | |
| 6 | BHVN | Biohaven Ltd. | Stock-Other | 3.65% | +2.08% | +46.88% | |
| 7 | TYRA | Tyra Biosciences Inc | Stock-Other | 3.36% | +0.48% | — | |
| 8 | PHVS | Pharvaris N.V. | Stock-Other | 3.35% | +3.32% | — | |
| 9 | PRAX | Praxis Precision Medicines I | Stock-Other | 3.15% | — | — | |
| 10 | ERAS | Erasca Inc | Stock-Other | 2.85% | -15.66% | EXIT | |
| 11 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 2.82% | — | — | |
| 12 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 2.78% | — | — | |
| 13 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.51% | -6.41% | EXIT | |
| 14 | TECX | Tectonic Therapeutic Inc | Stock-Other | 2.38% | +2.03% | — | |
| 15 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.14% | — | — | |
| 16 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 2.02% | +1.12% | — | |
| 17 | ANAB | Anaptysbio Inc | Stock-Other | 2.01% | — | — | |
| 18 | GHRS | GH Research PLC | Stock-Other | 1.49% | -2.24% | EXIT | |
| 19 | COGT | Cogent Biosciences Inc | Stock-Other | 1.49% | — | — | |
| 20 | VOR | Vor Biopharma Inc. | Stock-Other | 1.42% | — | — | |
| 21 | SCPH | Scpharmaceuticals Inc | Stock-Other | 1.17% | — | — | |
| 22 | ✓ | Rallybio CORP | Stock-Other | 1.09% | — | — | |
| 23 | QTTB | Q32 Bio Inc | Stock-Other | 1.01% | — | — | |
| 24 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 0.83% | — | — | |
| 25 | ✓ | Mersana Therapeutics Inc | Stock-Other | 0.59% | — | — | |
| 26 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.45% | +4.09% | — | |
| 27 | CDTX | Cidara Therapeutics Inc | Stock-Other | 0.15% | — | — | |
| 28 | EYPT | Eyepoint Inc | Stock-Other | 0.10% | +1.46% | — |
According to official SEC Form 13F filings, 5AM Venture Management, LLC reported a total U.S. public equity portfolio value of $287.9M across 28 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SKYE, TRDA, ELVN) accounted for 88.8% of total reported equity market value during Q2 2024.
During Q2 2024, 5AM Venture Management, LLC's top holdings by market value included SKYE (18.2%)、TRDA (14.1%)、ELVN (13.7%). The largest single position, SKYE, represented 18.2% of total portfolio value.
In Q2 2024, 5AM Venture Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.